KaydedilenlerDerginizi ekleyin

Dergiler / Epilepsi / 2017 / Cilt: 23 - Sayı: 2

Fokal nöbetli Hastalarda Lakosamid Ek Tedavisi İle İlgili Klinik Deneyimler

Clinical Experience with Adjunctive Lacosamide in Adult Patients with Focal Seizures

Demet ILHAN ALGIN
Oğuz Osman ERDİNÇ
Gönül AKDAĞ
Sayfa
57–62
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

After 6 months of LCM therapy, 49 patients (42.6%) had achieved reduc-tion in seizure frequency, with complete seizure suppression reported in 18.2% of patients (n=21).

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The aim of this study was to report first clinical experience in Turkey using lacosamide (LCM) as adjunctive therapy in patients with focal onset seizure.
📊
Temel Bulgular & Veri:Methods: Total of 128 adult patients with focal seizures (67 males and 61 females) were included in the study.
💡
Sonuç & Katkı:After 6 months of LCM therapy, 49 patients (42.6%) had achieved reduc-tion in seizure frequency, with complete seizure suppression reported in 18.2% of patients (n=21).
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: The aim of this study was to report first clinical experience in Turkey using lacosamide (LCM) as adjunctive therapy in patients with focal onset seizure. Methods: Total of 128 adult patients with focal seizures (67 males and 61 females) were included in the study. Thirteen of 128 patients were withdrawn from the study due to adverse events. In all, 22 of the patients used combination of 4 antiepileptic drugs (AEDs), 36 used 3 AEDs, 34 used 2 AEDs, and 28 used 1 AED. Seizure frequency and severity were evaluated according to patient diaries and history. Treatment response to LCM was determined by assessing change in seizure frequency after 6 months of LCM therapy. Responders were defined as patients who achieved seizure frequency reduction of ≥50%. Results: Mean age of the patients was 29.2 years (range: 18–53 years). After 6 months of LCM therapy, 49 patients (42.6%) had achieved reduc-tion in seizure frequency, with complete seizure suppression reported in 18.2% of patients (n=21). Response rate was

Abstract

Objectives: The aim of this study was to report first clinical experience in Turkey using lacosamide (LCM) as adjunctive therapy in patients with focal onset seizure.Methods: Total of 128 adult patients with focal seizures (67 males and 61 females) were included in the study. Thirteen of 128 patients were withdrawn from the study due to adverse events. In all, 22 of the patients used combination of 4 antiepileptic drugs (AEDs), 36 used 3 AEDs, 34 used 2 AEDs, and 28 used 1 AED. Seizure frequency and severity were evaluated according to patient diaries and history. Treatment response to LCM was determined by assessing change in seizure frequency after 6 months of LCM therapy. Responders were defined as patients who achieved seizure frequency reduction of ≥50%.Results: Mean age of the patients was 29.2 years (range: 18–53 years). After 6 months of LCM therapy, 49 patients (42.6%) had achieved reduc-tion in seizure frequency, with complete seizure suppression reported in 18.2% of patients (n=21). Response rate was

🔖

Bu Makaleye Atıf Yap

ALGIN, D. I., ERDİNÇ, O. O., AKDAĞ, G. (2022). Fokal nöbetli Hastalarda Lakosamid Ek Tedavisi İle İlgili Klinik Deneyimler. Epilepsi, Cilt: 23 - Sayı: 2, 57–62. https://ajindex.com/articles/501670

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Sake JK, Hebert D, Isojärvi J, Doty P, De Backer M, Davies K, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010
  2. 24(12):1055–68. 25. Harden CL, Cohn A, Lowe M, Serrano E. Initial post marketing experience with lacosamide in adult patients with epilepsy. Epilepsy Res 2012
  3. 98(2-3):260–3. 24. Bootsma HP, Ricker L, Hekster YA, Hulsman J, Lambrechts D, Ma-joie M, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure 2009
  4. 18(5):327–31. 23. Wehner T, Bauer S, Hamer HM, Hattemer K, Immisch I, Knake S, et al. Six months of postmarketing experience with adjunc-tive lacosamide in patients with pharmacoresistant focal epi-lepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009
  5. 16(3):423–5. 22. Flores L, Kemp S, Colbeck K, Moran N, Quirk J, Ramkolea P, et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK). Seizure 2012
  6. 21(7):512–7 21. Villanueva V, Garcés M, López-Gomáriz E, Serratosa JM, González-Giráldez B, Parra J, et al. Early add-on lacosamide in a real-life setting: results of the REALLY study. Clin Drug Investig 2015
  7. 35(2):121–31. 20. Zadeh WW, Escartin A, Byrnes W, Tennigkeit F, Borghs S, Li T, et al. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial. Seizure 2015
  8. 72–9. 19. Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav 2015
  9. 52(Pt A):119–27 18. Ben-Menachem E. Lacosamide: an investigational drug for ad-junctive treatment of partial-onset seizures. Drugs Today (Barc) 2008
  10. 44(1):35–40. 17. Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A, et al. Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure 2013
  11. 22(3):210–6. 16. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized con-trolled trial. Epilepsia 2009
  12. 50(3):443–53. 15. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P